Portal Hypertension Surgery — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Portal hypertension is elevation of the portal venous pressure above 5 mmHg — clinically significant portal hypertension is defined as a hepatic venous pressure gradient (HVPG) of 10 mmHg or more. It develops when blood flow through the liver is obstructed — most commonly by cirrhosis, which causes structural distortion of the hepatic sinusoids from fibrosis and nodule formation. Elevated portal pressure forces blood through portosystemic collateral pathways, particularly the oesophageal and gastric submucosal venous plexuses, causing varices that can rupture with life-threatening haemorrhage.

Portal hypertension surgery encompasses the interventional and surgical procedures that reduce portal venous pressure or bypass the obstructed portal circulation to prevent or control its complications — principally variceal haemorrhage, refractory ascites, hepatic hydrothorax, and hepatorenal syndrome. The primary treatment options are: (1) Transjugular intrahepatic portosystemic shunt (TIPS) — a minimally invasive radiological procedure that creates a direct channel within the liver between the portal and hepatic venous systems using a covered metallic stent-graft; (2) Surgical portosystemic shunts — open operations that surgically connect the portal vein or its tributaries to the systemic venous system to decompress the portal circulation; and (3) Liver transplantation — which simultaneously replaces the diseased liver and permanently eliminates portal hypertension, offering the only definitive curative treatment for cirrhotic portal hypertension.

Selection between the three modalities (TIPS, surgical shunts, liver transplantation) is guided by the severity of liver disease (Child-Pugh class, MELD score), specific portal hypertension complication, and eligibility for transplantation.

Indications for TIPS: - Recurrent or refractory variceal haemorrhage uncontrolled or at high risk of recurrence despite optimal endoscopic band ligation plus non-selective beta-blockers (propranolol or carvedilol) - Early TIPS: Placement within 72 hours of index variceal haemorrhage in Child-Pugh C (10-13 points) or Child-Pugh B with active bleeding at endoscopy — reduces 6-week mortality from 30-40% to under 15% in randomised trials - Refractory ascites (accumulation despite diuretic therapy at maximum tolerated dose): TIPS reduces ascites recurrence rate by 60-70% and is superior to repeated large-volume paracentesis in randomised trials - Hepatic hydrothorax (pleural effusion from ascites crossing the diaphragm) refractory to medical therapy - Budd-Chiari syndrome (hepatic vein outflow obstruction): TIPS restores hepatic outflow - Bridge to liver transplantation in patients with frequent variceal bleeding

Indications for surgical portosystemic shunts: Largely superseded by TIPS, surgical shunts are considered when TIPS is technically inaccessible (portal vein thrombosis with cavernous transformation, anatomical inaccessibility), TIPS has failed or occluded, or in young patients with non-cirrhotic portal hypertension (portal vein thrombosis, schistosomiasis) with preserved hepatic synthetic function where surgical durability is superior to TIPS.

Indications for liver transplantation: Patients with decompensated cirrhosis (Child-Pugh C, MELD above 15) causing portal hypertension complications who meet eligibility criteria — absence of active alcohol or substance use (minimum 6 months abstinence), no untreated malignancy outside Milan criteria, adequate social support, and absence of irreversible organ failure precluding survival.

Contraindications to TIPS: Severe hepatic encephalopathy is a relative contraindication as TIPS may worsen encephalopathy. Absolute contraindications include primary prevention of first variceal bleed (no benefit in trials), congestive heart failure (increased cardiac output burden), uncontrolled systemic infection, and severe pulmonary hypertension.

Each of the three treatment modalities uses a distinct technique suited to its clinical indication.

Transjugular intrahepatic portosystemic shunt (TIPS): TIPS is performed in an angiography suite under fluoroscopic guidance with conscious sedation. A catheter is introduced via the right internal jugular vein and advanced into the right hepatic vein. A needle is advanced from the hepatic vein through the liver parenchyma into a major branch of the portal vein, guided by CO2 portography or intravascular ultrasound. The hepatic venous pressure gradient is measured before and after the procedure. A polytetrafluoroethylene (PTFE)-covered stent-graft (8-12 mm diameter) is deployed across the liver parenchyma to create a permanent channel connecting the portal and hepatic venous systems. The target post-TIPS HVPG is below 12 mmHg (which prevents variceal haemorrhage) or below 8 mmHg (which also controls ascites). The procedure takes 1-4 hours depending on anatomical complexity.

Surgical portosystemic shunts: Performed under general anaesthesia through an upper abdominal incision. The distal splenorenal shunt (Warren shunt) selectively decompresses oesophageal varices by connecting the splenic vein to the left renal vein, preserving hepatic portal perfusion and reducing encephalopathy risk compared with non-selective shunts. The mesocaval shunt connects the superior mesenteric vein to the inferior vena cava using a synthetic graft, suitable when the splenic vein is unsuitable. Non-selective shunts (portocaval anastomosis) are rarely used today as they divert all portal flow away from the liver, worsening encephalopathy.

Liver transplantation: Orthotopic liver transplantation requires a donor organ from a brain-dead donor or, increasingly, a living donor partial hepatectomy providing the right lobe. The recipient operation involves complete hepatectomy of the diseased liver and vascular anastomosis of the donor organ's hepatic artery, portal vein, hepatic vein, and bile duct reconstruction. Surgery takes 6-12 hours. Immunosuppression with tacrolimus is commenced immediately and maintained lifelong.

The efficacy of each portal hypertension intervention depends on the specific complication treated and the underlying hepatic reserve.

TIPS for variceal haemorrhage: TIPS controls acute variceal haemorrhage in 90-95% of cases when endoscopic therapy has failed. Early TIPS (within 72 hours) in high-risk Child-Pugh C patients reduces 6-week mortality from approximately 35% to under 15% — a dramatic improvement in outcome in the highest-risk group (Garcia-Tsao 2017 meta-analysis, Hernandez-Gea 2019 RCT). PTFE-covered stents maintain 1-year patency in over 85% of patients and reduce rebleeding risk by 70% compared with endoscopic therapy plus beta-blockers alone.

TIPS for refractory ascites: For patients requiring monthly or more frequent large-volume paracentesis (LVP), TIPS achieves complete response (no further paracentesis) in 50-60% and partial response in a further 30% at 12 months. Randomised trials demonstrate superiority of TIPS over repeated LVP in transplant-free survival for selected patients with good hepatic function (MELD below 18).

Surgical shunts: Distal splenorenal shunts achieve 5-year variceal rebleeding prevention in 80-85% of patients with non-cirrhotic portal hypertension and preserved liver function, with lower encephalopathy rates than non-selective shunts.

Liver transplantation: For patients meeting transplant criteria, orthotopic liver transplantation achieves 5-year survival of 70-80%, definitively eliminating portal hypertension, reversing hepatic encephalopathy, and improving quality of life. Liver transplantation following TIPS as a bridge procedure has equivalent outcomes to non-TIPS bridged transplantation.

Each portal hypertension procedure carries a specific complication profile that must be weighed against the alternative of continued portal hypertension complications.

TIPS complications: - Hepatic encephalopathy: The most common complication, occurring in 20-30% of patients within 3 months of TIPS placement. Blood flow bypassing the liver delivers ammonia and other hepatotoxic substances directly to the systemic circulation. Managed with lactulose, rifaximin, and in severe cases, TIPS diameter reduction (revision to a smaller stent). - Technical failure: Inability to access the portal vein occurs in 2-5% due to portal vein thrombosis or anatomical difficulty. - Haemoperitoneum: Inadvertent capsular puncture causing intraperitoneal haemorrhage in under 1%. - Cardiac decompensation: TIPS increases cardiac preload by 25-35% — dangerous in patients with cardiac dysfunction, right heart failure, or pulmonary hypertension. - Stent dysfunction: Covered stents have primary patency above 85% at 1 year. Stenosis or occlusion requires revision angioplasty or restenting.

Surgical shunt complications: - Operative mortality: Higher than TIPS (5-10%) in Child-Pugh B/C patients; excellent (under 2%) in non-cirrhotic patients with preserved hepatic function. - Hepatic encephalopathy: Non-selective shunts cause encephalopathy in 30-50%; selective distal splenorenal shunts in 10-15%. - Graft thrombosis: Mesocaval graft shunts may thrombose (10-20% at 5 years), requiring reoperation.

Liver transplantation complications: - Primary non-function of the donor organ (under 5%) - Rejection episodes (acute cellular rejection in 20-30%, managed with pulsed steroids) - Biliary complications — bile leak or anastomotic stricture in 5-15% - Immunosuppression-related infections and metabolic complications (new-onset diabetes, hypertension, dyslipidaemia, renal impairment)

Recovery from portal hypertension procedures varies dramatically depending on the intervention.

After TIPS (Days 0-7): Patients are typically hospitalised for 3-7 days after TIPS placement. The first 48-72 hours focus on monitoring for immediate complications: hepatic encephalopathy (daily neurological assessment), haemorrhage, cardiac decompensation, and access-site haematoma. Doppler ultrasound is performed within 24 hours to confirm stent patency and adequate portal decompression. Oral feeding usually resumes on the first post-procedure day. Diuretic therapy is continued for ascites control, with doses adjusted as the TIPS reduces hepatic sinusoidal pressure.

After TIPS (Weeks 1-4): Outpatient encephalopathy monitoring is performed at 2 and 4 weeks, as the highest risk of de-novo encephalopathy is in the first 4 weeks. Lactulose is prescribed prophylactically for patients at risk. Dietary sodium restriction (less than 2 g/day) continues for ascites management.

Stent surveillance: Duplex ultrasound surveillance at 3 months, 6 months, and annually thereafter monitors stent patency and flow velocity. A portal vein flow velocity below 30-50 cm/second indicates stent dysfunction. TIPS revision (balloon angioplasty or additional stenting) maintains patency in over 90% of revision procedures.

After liver transplantation (Weeks 0-4): Intensive care unit monitoring for 2-5 days for haemodynamic stability, liver function (AST, bilirubin, clotting), bile output, and immunosuppression adjustment. Hospital stay averages 14-21 days. Tacrolimus blood levels are monitored daily and adjusted to therapeutic windows. Rejection episodes are treated with pulsed methylprednisolone.

Long-term after transplant: Lifelong tacrolimus-based immunosuppression with annual liver function testing, renal function monitoring, metabolic surveillance (blood pressure, glucose, lipids), and surveillance for post-transplant malignancy (skin, lymphoma). Recurrence of the primary liver disease (hepatitis C, hepatitis B, NASH, autoimmune hepatitis) requires ongoing management. Five-year follow-up shows 80% of transplant recipients returning to full-time employment or normal daily activities.